Bristol-Myers Squibb Stock Is Falling as Celgene Deal Faces Setback - Barron's
Investors in the pharmaceutical company Bristol-Myers Squibb have a bad case of the Mondays. Shares of the company dropped sharply in pre-market trading, ...
View full coverage on Google News